[go: up one dir, main page]

ECSP20046463A - Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas - Google Patents

Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas

Info

Publication number
ECSP20046463A
ECSP20046463A ECSENADI202046463A ECDI202046463A ECSP20046463A EC SP20046463 A ECSP20046463 A EC SP20046463A EC SENADI202046463 A ECSENADI202046463 A EC SENADI202046463A EC DI202046463 A ECDI202046463 A EC DI202046463A EC SP20046463 A ECSP20046463 A EC SP20046463A
Authority
EC
Ecuador
Prior art keywords
compounds
compositions
acidic
methods
diseases
Prior art date
Application number
ECSENADI202046463A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Yana Reshetnyak
Don Engleman
Oleg Andreev
Johanna Marie Csengery
Robert A Volkmann
Dalton King
Original Assignee
Cybrexa 1 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 1 Inc filed Critical Cybrexa 1 Inc
Publication of ECSP20046463A publication Critical patent/ECSP20046463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos para el tratamiento de enfermedades con tejidos con enfermedad ácida o hipóxica y composiciones farmacéuticas que comprenden los compuestos, así como métodos para preparar y usar los compuestos y las composiciones.
ECSENADI202046463A 2018-01-05 2020-08-04 Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas ECSP20046463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862613931P 2018-01-05 2018-01-05
US201862758264P 2018-11-09 2018-11-09

Publications (1)

Publication Number Publication Date
ECSP20046463A true ECSP20046463A (es) 2020-12-31

Family

ID=65411925

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202046463A ECSP20046463A (es) 2018-01-05 2020-08-04 Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas

Country Status (18)

Country Link
US (2) US10933069B2 (es)
EP (1) EP3735297A1 (es)
JP (2) JP7356450B2 (es)
KR (1) KR20200121800A (es)
CN (1) CN111989137A (es)
AU (1) AU2019205325A1 (es)
BR (1) BR112020013672A2 (es)
CA (1) CA3088858A1 (es)
CL (1) CL2020001797A1 (es)
CR (1) CR20200334A (es)
EC (1) ECSP20046463A (es)
IL (1) IL275754A (es)
MA (1) MA51524A (es)
MX (1) MX2020007060A (es)
PE (1) PE20211305A1 (es)
PH (1) PH12020551043A1 (es)
TW (1) TWI820077B (es)
WO (1) WO2019136298A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634498A4 (en) * 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education BOUND COMPOUNDS AND OTHER PH ACTIVATED COMPOUNDS
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
US10633383B2 (en) 2018-01-05 2020-04-28 Ac Immune Sa Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CN112939966B (zh) * 2019-12-10 2023-03-24 武汉光谷亚太医药研究院有限公司 嘧啶衍生物、其制备及应用
US20230141981A1 (en) 2020-01-21 2023-05-11 Shanghai Micurx Pharmaceuticals Co., Ltd Novel compounds and composition for targeted therapy of kidney-associated cancers
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
PE20240119A1 (es) * 2021-01-08 2024-01-22 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
CN115137818B (zh) * 2021-03-31 2023-06-27 华南师范大学 谷胱甘肽激活的光敏剂-化疗药一体化分子前药及其应用
EP4319755A4 (en) 2021-04-08 2025-03-26 Board of Regents, The University of Texas System Compounds and methods for theranostic targeting of parp activity
CN117897175A (zh) 2021-04-29 2024-04-16 美商斯布雷克萨二号公司 拓扑异构酶i抑制剂的肽缀合物的给药方案
KR102677962B1 (ko) * 2022-03-02 2024-06-25 고려대학교 산학협력단 루카파립의 개선된 제조방법
CN116640229B (zh) * 2023-04-10 2024-01-30 中国人民解放军总医院第五医学中心 一种低pH靶向性CAR-T细胞的构建及应用
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225465A1 (en) 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
MY132496A (en) * 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
JP2002528531A (ja) 1998-11-03 2002-09-03 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−フェニルベンズイミダゾール、その製造法および使用
WO2000042040A1 (en) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
BR0016328A (pt) 1999-12-13 2002-08-27 Lilly Co Eli Pró-drogas de fosfato de pseudomicina
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
MXPA04008999A (es) 2002-03-20 2004-12-07 Squibb Bristol Myers Co Profarmacos de fosfato de fluorooxindoles.
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
PT1660095E (pt) * 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
WO2006033003A1 (en) 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
WO2006033007A2 (en) 2004-09-22 2006-03-30 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
AU2006206428B2 (en) 2005-01-18 2009-07-16 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN101316834A (zh) 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
RS53082B (sr) * 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. Kombinovana terapija sa parp inhibitorima
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
ES2617619T3 (es) * 2008-06-05 2017-06-19 Janssen Pharmaceutica, N.V. Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
WO2012047354A2 (en) 2010-07-13 2012-04-12 Rhode Island Board Of Governors For Higher Education Environmentally sensitive compositions
EP2603201B1 (en) * 2010-08-13 2020-03-11 Rhode Island Board of Governors for Higher Education Liposome compositions and methods of use thereof
CN111569086B (zh) 2013-12-19 2024-06-21 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN113209033A (zh) 2014-08-22 2021-08-06 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
PT3204018T (pt) * 2014-10-07 2021-11-12 Immunomedics Inc Uso neoadjuvante de conjugados anticorpo-fármaco
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
KR102407261B1 (ko) 2015-02-27 2022-07-06 서울대학교산학협력단 나노 항암제형 및 그 제조 방법
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
US10435428B2 (en) 2015-11-24 2019-10-08 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) * 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
EP3554638B1 (en) * 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education BOUND COMPOUNDS AND OTHER PH ACTIVATED COMPOUNDS
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics

Also Published As

Publication number Publication date
US12427157B2 (en) 2025-09-30
CR20200334A (es) 2021-03-09
MX2020007060A (es) 2020-11-11
IL275754A (en) 2020-08-31
KR20200121800A (ko) 2020-10-26
WO2019136298A1 (en) 2019-07-11
TWI820077B (zh) 2023-11-01
MA51524A (fr) 2020-11-11
BR112020013672A2 (pt) 2020-12-01
CN111989137A (zh) 2020-11-24
PH12020551043A1 (en) 2021-09-06
PE20211305A1 (es) 2021-07-20
AU2019205325A1 (en) 2020-08-13
JP2024009819A (ja) 2024-01-23
US20210299137A1 (en) 2021-09-30
US20190209580A1 (en) 2019-07-11
JP2021510173A (ja) 2021-04-15
TW201938540A (zh) 2019-10-01
US10933069B2 (en) 2021-03-02
CA3088858A1 (en) 2019-07-11
EP3735297A1 (en) 2020-11-11
CL2020001797A1 (es) 2021-01-29
JP7356450B2 (ja) 2023-10-04

Similar Documents

Publication Publication Date Title
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
MX2021009673A (es) Moduladores de ror-gamma.
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CL2019002583A1 (es) Inhibidores duales de magl y faah.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet